LEP and Hepatic fibrosis: Interestingly, Makled and his coworkers recently reported another pathway of saroglitazar affecting liver fibrosis, which means that saroglitazar is able to improve liver fibrosis in TAA-induced liver fibrosis models of rats via suppressing leptin, transforming growth factor-β1 (TGFβ1), tissue inhibitor of metalloproteinases-1 (TIMP-1), and platelet-derived growth factor-BB (PDFG-BB) [61].